



---

**For Immediate Release**  
**March 22, 2018**

**Contacts:** Steven Grossman 1-301-539-9660  
Ladd Wiley 202-549-3595

***In response to press inquiries, the Alliance for a Stronger FDA issued the following statement:***

The Alliance thanks House and Senate appropriators for their continued support of the FDA. The agency provides services that are core functions of government and, because of this, appropriators have clearly recognized the need for a strong FDA that benefits the American people.

We also appreciate that the Administration—through its FY 19 budget request—has given FDA a vote of confidence. We look forward to working with appropriators and the Administration in the FY 19 process to make the agency even more effective and to realize the multiple opportunities to increase the value of its work.

Compared to the last FY 18 Continuing Resolution, the Omnibus Appropriations Act will add significant resources this year. The key changes are:

- \$41 million in addition BA appropriations, with a focus on improvements in food safety, enhancing the Oncology Center of Excellence initiative and managing increased workloads in the animal drugs and feed programs.
- \$94 million to support expansion of FDA’s role in combatting opioid abuse, using monies provided under a general provision (i.e. does not increase FDA’s BA base funding).

In addition, appropriators have chosen to support implementation of the 21<sup>st</sup> Century Cures Act with \$60 million dollars drawn from a pre-paid fund (i.e. not BA) set up by that Act. This is an increase from \$20 million available under the Act in 2017.

While the opioid monies will not increase FDA’s core funding, they should allow the agency to free up some resources that have been pulled from existing programs to help stem the opioid crisis.

The Alliance feels confident that FDA will be worthy of the trust that comes with these additional dollars and are committed to working with appropriators and Commissioner Gottlieb to assure that funds are used appropriately and to the benefit of the American people.

# FY 18 Budget Authority Appropriations for FDA from the Omnibus Appropriations Act

3-22-18 (subject to further revision)

## Compared to FY 16 and FY 17

**Not all numbers add due to rounding**

**\*\*Numbers from prior years may not reflect post-appropriations adjustments\*\***

Budget authority only, by center; no user fees	FY 16 Final	FY 17 Final	FY 18 Omnibus 3-22-18	FY 18 Compared to FY 17
Food	\$ 987 million	\$1.026 billion	<b>\$1.042 million</b>	+ \$16 million
Human Drugs	\$ 492 million	\$ 492 million	<b>\$ 496 million</b>	+\$ 4 million
Biologics	\$ 215 million	\$ 215 million	<b>\$ 215 million</b>	NC
Animal Drugs/Feed	\$ 159 million	\$ 163 million	<b>\$ 173 million</b>	+\$10 million
Devices & Radiological Health	\$ 323 million	\$ 330 million	<b>\$ 330 million</b>	NC
Natl. Ctr. For Toxic. Research	\$ 63 million	\$ 63 million	<b>\$ 63 million</b>	NC
HQ, Officer. of Commissioner & Other	\$ 183 million	\$ 185 million	<b>\$ 196 million</b>	+\$11 million
Rent & Facilities Cost	\$ 298 million	\$ 285 million	<b>\$ 285 million</b>	NC
<b>SUBTOTAL, Salaries &amp; Expenses</b>	<b>\$ 2.721 billion</b>	<b>\$ 2.759 billion</b>	<b>\$2.800 billion</b>	<b>+\$41 million</b>
Building and Facilities Repair	\$ 9 million	\$ 12 million	<b>\$ 12 million</b>	NC
<b>All BA Approps Total--no user fee</b>	<b>\$ 2.730 billion</b>	<b>\$ 2.771 billion</b>	<b>\$2.812 billion</b>	<b>+\$41 million</b>

Additional non-user fee funds made available to FDA in FY 18, but not included in FDA BA base:

---Discretionary: general provision that allots FDA \$94 million to address the opioid crisis

----Pre-funded, not BA: statutory level of \$60 million for implementation of 21<sup>st</sup> Century Cures (increase from \$20 million in FY 17).

**For more information:**

Steven Grossman, [sgrossman@strengthenfda.org](mailto:sgrossman@strengthenfda.org), 301-539-9660

Ladd Wiley, [lwiley@ofwlaw.com](mailto:lwiley@ofwlaw.com), 202-549-3595